Raphael Pharmaceutical (RAPH) Other Working Capital Changes (2020 - 2025)
Raphael Pharmaceutical (RAPH) reported Other Working Capital Changes of -$6000.0 for Q3 2025, down 300.0% on a YoY basis from $3000.0 in Q3 2024, and up 81.82% sequentially from -$33000.0 in Q2 2025.
Raphael Pharmaceutical (RAPH) Other Working Capital Changes (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical (RAPH) has 6 years of Other Working Capital Changes data on file, last reported at -$6000.0 in Q3 2025.
- For the quarter ending Q3 2025, Other Working Capital Changes fell 300.0% year-over-year to -$6000.0; the trailing twelve-month figure through Sep 2025 stood at -$7000.0 (down 216.67% YoY), and the FY2024 full-year result was -$1000.0, up 97.22% from the prior year.
- Other Working Capital Changes improved to -$6000.0 in Q3 2025, from -$33000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $244000.0 in Q4 2021 to a low of -$170000.0 in Q1 2022.
- A 5-year average of -$11894.7 and a median of -$4000.0 in 2021 frame the typical range for Other Working Capital Changes.
- Peak annual rise in Other Working Capital Changes reached 483.33% in 2025, while the deepest fall reached 371.43% in 2025.
- Tracing RAPH's Other Working Capital Changes over 5 years: stood at $244000.0 in 2021, then tumbled by 93.03% to $17000.0 in 2022, then sank by 76.47% to $4000.0 in 2023, then slumped by 175.0% to -$3000.0 in 2024, then slumped by 100.0% to -$6000.0 in 2025.
- Business Quant data shows RAPH's Other Working Capital Changes at -$6000.0 in Q3 2025, -$33000.0 in Q2 2025, and $35000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -6,000.00 |
| Sep 30, 2025 | -6,000.00 |
| Sep 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -33,000.00 |
| Jun 30, 2025 | -33,000.00 |
| Jun 30, 2025 | -33,000.00 |
| Mar 31, 2025 | 35,000.00 |
| Mar 31, 2025 | 35,000.00 |
| Mar 31, 2025 | 35,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Jun 30, 2024 | -7,000.00 |
| Jun 30, 2024 | -7,000.00 |
| Jun 30, 2024 | -7,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Mar 31, 2024 | 6,000.00 |